Tarceva

Type: Product
Name: Tarceva
First reported 12 hours ago - Updated 4 hours ago - 2 reports

Survival benefits with erlotinib plus bevacizumab in EGFR -Mutated NSCLC

medwireNews: Combining erlotinib with bevacizumab could prolong progression-free survival (PFS) in patients being treated for epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), phase II trial results suggest.This addition ... [Published MedWire News - 4 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

No Survival Benefits With Erlotinib and Whole-Brain Radiotherapy for NSCLC With Multiple Brain Metastases

By Charlotte BathSeptember 15, 2014, Volume 5, Issue 15“To exploit the potential radiosensitizing properties, the direct effect on brain metastases, and systemic activity of erlotinib,” researchers from the United Kingdom tested concurrent erlotinib and ... [Published The ASCO Post - 8 hours ago]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma

by Jeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, Chung-Yu Chen, Cheng-Yu Chang, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Chih-Wei Wu, Cheng-Ta Yang, Yuh-Min Chen, Gee-Chen ChangIntr ... [Published Plosone.org - Sep 13 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

NSCLC treatment market set to grow to more than $7.9 billion by 2020

The global non-small cell lung cancer (NSCLC) treatment market value will increase from $5.1 billion in 2013 to slightly over $7.9 billion by 2020, expanding at a compound annual growth rate (CAGR) of 6.6%.According to the latest report from business ... [Published Pharma Letter - Sep 09 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Merrimack Pharmaceuticals : "Methods for Preventing Toxic Drug-Drug Interactions in Combination Therapies Comprising Anti-Erbb3 Agents" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Biotech Business Week -- A patent application by the inventors Onsum, Matthew David ( San Francisco, CA ); Niyikiza, Clet ( Gulph Mills, PA ); Moyo, Victor ( Ringoes, NJ ); Kubasek, William ( Belmont, MA ); Czibere, ... [Published 4 Traders - Sep 04 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib ... [Published The Oncologist - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 5 reports

‘Miriam for president’ Senator says she can ‘rise to the occasion’

BY PRINCE GOLEZManila ReporterMANILA – Iloilo City’s Sen. Miriam Defensor-Santiago, battling stage 4 lung cancer, may run for president in 2016.“I am not going to be coy. Society leaders have urged me to seek the presidency,” said Santiago.The feisty ... [Published Panay News - Aug 27 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Investigators at National Taiwan University Discuss Findings in Cancer Gene Therapy (CIP2A mediates erlotinib-induced apoptosis in non-small cell...

Investigators at National Taiwan University Discuss Findings in Cancer Gene Therapy (CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation)By a News Reporter-Staff News Editor at Cancer Gene Therapy Week ... [Published HispanicBusiness.com - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Forum Post: RE: Tarceva

Hi Carol.I have been on Tarceva for just over a year. For me it has been very easy to tolerate.I have carried on working and the side effects have been mostly short lived and manageable. First side effects usually appear in a few days and normally a rash ... [Published Macmillan Cancer Support - Aug 26 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show.To determine the clinical significance of KRAS mutational status in response to erlotinib, Balazs Dome (Medical University ... [Published News-Medical.Net - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

NIH launches 3 integrated precision medicine trials

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, was launched to identify early-stage lung cancer patients with tumours that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted ... [Published PharmaBiz - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

ReferencesHuebner G, Link H, Kohne CH, et al: Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44-49.Hainsworth ... [Published Sexual Development - Aug 19 2014]

Quotes

...and development in both pharma and biotech settings, spanning small molecules and biologics," said Jonathan Lim, M D , Chairman and CEO of Ignyta. "His deep understanding of oncology, coupled with his extensive experience in translational medicine and the integration of biomarker strategies in discovery and development programs, will help drive Ignyta's success as we strive to provide new oncology treatment options for patients."
"Therefore, in one aspect, a method of treatment is provided for preventing a toxic DDI resulting from combination therapy treatment of a cancer patient with an anti-ErbB3 agent and a TKI or AAGB wherein a first TKI or AAGB dosage has been recommended by a manufacturer of the TKI or AAGB for administration of the TKI or AAGB in the absence of co-administered anti-ErbB3 agent and a second TKI or AAGB dosage has been recommended or suggested for consideration by the manufacturer or distributor for administration of the TKI or AAGB in the presence of co-administered anti-ErbB3 agent, which second dosage is a reduced dosage that provides a reduced dosage of the TKI or AAGB as compared to the first dosage; the method comprising co-administering the TKI and the anti-ErbB3 agent to the cancer patient, with the TKI administered according to the reduced dosage."

More Content

All (157) | News (127) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Survival benefits with erlotinib plus bevacizum... [Published MedWire News - 4 hours ago]
No Survival Benefits With Erlotinib and Whole-B... [Published The ASCO Post - 8 hours ago]
Vaibhav Choukse: Sweetheart deals that hurt con... [Published Business Standard India - 10 hours ago]
In Advanced Lung Cancer, Targeted Combinations ... [Published The ASCO Post - 12 hours ago]
AVEO Oncology: A New Platform To Create Oncolog... [Published Seeking Alpha - Sep 15 2014]
Impact of EGFR Mutation Detection Methods on th... [Published Plosone.org - Sep 13 2014]
The New Rules of Pharma Marketing [Published Insead Knowledge - Sep 11 2014]
NSCLC treatment market set to grow to more than... [Published Pharma Letter - Sep 09 2014]
Oncology Diagnostics [Published Clinical Lab Products - Sep 09 2014]
Ignyta Appoints Robert Wild, Ph.D., as Chief Sc... [Published Scottrade - Sep 08 2014]
Paraneoplastic pruritus presenting with Hodgkin... [Published 7thSpace - Sep 08 2014]
Cancer survivor fights for education, research [Published U-T San Diego - Sep 05 2014]
Merrimack Pharmaceuticals : "Methods for Preven... [Published 4 Traders - Sep 04 2014]
Miriam files bill on gov’t funding for regenera... [Published GMA News Online - Sep 02 2014]
Failure of IGF-1R Inhibitor Figitumumab in Adva... [Published The ASCO Post - Sep 02 2014]
NIH Announces Launch of Precision Medicine Tria... [Published The ASCO Post - Sep 02 2014]
When will they find a cancer cure, doc? [Published Guardian.co.uk - Sep 01 2014]
Roche Sees Second Phase III Setback of 2014 as ... [Published Genetic Engineering News - Aug 29 2014]
A Phase I/II Study Combining Erlotinib and Dasa... [Published The Oncologist - Aug 29 2014]
Mutant allele frequency predicts lung cancer TK... [Published News-Medical.Net - Aug 28 2014]
Researchers Submit Patent Application, "Method ... [Published 4 Traders - Aug 28 2014]
AJINOMOTO : Patent Application Titled "Therapeu... [Published 4 Traders - Aug 28 2014]
Investigators at National Taiwan University Dis... [Published HispanicBusiness.com - Aug 28 2014]
Efficacy of Second-Line Oxaliplatin, Leucovorin... [Published Chemotherapy Advisor - Aug 27 2014]
‘Miriam for president’ Senator says she can ‘ri... [Published Panay News - Aug 27 2014]
Miriam hints at running for president in 2016 p... [Published Philippines Daily Tribune - Aug 27 2014]
Recovering from cancer, Miriam eyes presidency ... [Published Philippine Star - Aug 27 2014]
Miriam says she has beaten cancer, may run for ... [Published Interaksyon - Aug 27 2014]
‘Recovering’ Miriam might run for president [Published Rappler - Aug 27 2014]
Diagnostics are rising up the pharma value chain [Published PMLive - Aug 27 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Advancing medicine, layer by layer [Published MIT News feed - Jul 01 2014]
Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor Paula Hammond's lab at MIT. Morton's work ...
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Jun 19 2014]
NEW YORK, June 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Tarceva Forecasthttp://www.reportlinker.com/p02162048/Tarceva-Forecast.htmlThe BCC Research Tarceva Forecast is a quantitative ...
Faculty highlight: Paula Hammond [Published MIT News feed - Jun 18 2014]
As a chemical engineer, Paula Hammond began her career getting tiny polymers to transform when heated or stretched — by changing color, for example. But her passion turned to using those techniques to promote healing. That led her to engineer better ...
FibroGen Announces Results of Phase 2 Study of ... [Published Business Wire Health News - May 31 2014]
CHICAGO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally ...
Genprex Begins Phase II Clinical Trial for Lung... [Published PR Newswire: Health - May 20 2014]
AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.